Podcast
Medical News Podcast
Hosted by PeerDirect · EN
The Medical News Podcast by PeerDirect delivers news and interviews with clinical thought leaders and researchers to keep you informed of the latest breakthroughs, guidelines, and insights in your specialty. Designed for clinicians with stories selected by the PeerDirect editorial board. Visit us at peerdirect.com to sign-up for our newsletter.
87episodes
Episodes
Newest firstAll episodes
Can We Predict Kidney Function Decline in Patients With Lupus Nephritis?
Jul 300:08:36Tap to summarizeDrs. Kalunian and McMahon explain how inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) in lupus nephritis is not inert scarring, but rather an active, prognostically powerful process that strongly predicts the decline of estimated glomerular filtration rate. They argue that recognizing and routinely scoring i-IFTA could transform clinical practice by shifting focus beyond glomerular lesions to the tubulointerstitial compartment, opening new avenues for risk stratification and potentially for targeted therapy.
Transcribe →Can artificial intelligence prevent a life-threatening hypoglycemic event before it happens?
Jul 200:05:48Tap to summarizeArtificial intelligence may soon help clinicians prevent inpatient hypoglycemia before it occurs, while new decade-long follow-up data suggest CAR-T therapy may provide durable cures for selected patients with B-cell lymphoma. We also review a personalized statin muscle-risk calculator designed to improve shared decision-making and highlight new evidence supporting consistent resistance training as an important strategy for long-term type 2 diabetes prevention.
Transcribe →Beyond Asthma and Eczema: Navigating Biologics for Multimorbid Allergic Patients
Jul 100:11:42Tap to summarizeDrs. Newhall and Gupta discuss how biologic therapies are transforming care for patients with multiple allergic diseases—such as asthma, atopic dermatitis, nasal polyps, food allergy, and eosinophilic esophagitis—while also making treatment decisions more complex. They explain how they choose among biologics like dupilumab, omalizumab, IL‑5 blockers, and TSLP inhibitors by focusing on biomarkers, age, comorbidities, and which condition most affects the patient’s quality of life.
Transcribe →Has the HPV vaccine already eliminated cervical cancer deaths in a generation of young women?
Jun 3000:04:33Tap to summarizeThis episode of the PeerDirect Medical News Podcast highlights three studies with potential implications for prevention, pulmonary medicine, and infectious disease management. Topics include the first national-level evidence that HPV vaccination prevents cervical cancer deaths, Phase III data showing tezepelumab can reduce chronic oral corticosteroid use in severe asthma while maintaining disease control, and new evidence supporting cefazolin as a safer treatment option for MSSA bacteremia with comparable survival outcomes and less nephrotoxicity.
Transcribe →Vaccination and Response in Patients With CLL
Jun 2400:12:28Tap to summarizeDrs. Cohen and Chang review how CLL and its treatments weaken the immune system and lead to poorer responses to vaccines. Even though vaccine protection is often reduced, the experts emphasize that vaccination remains a key strategy for infection prevention, alongside careful timing around therapy and proactive counseling for patients and their families.
Transcribe →NCCN 2026 Breast Cancer Congress Updates
Jun 2300:10:18Tap to summarizeDrs. Waks and Sammons discuss how new long-term data and key updates in the NCCN Guidelines® are reshaping treatment strategies for HER2+ breast cancer in both early-stage and metastatic settings. They highlight the growing role of T-DXd, including its benefits, risks, and optimal patient selection, alongside how to sequence it with other HER2-directed therapies like pertuzumab and T-DM1.
Transcribe →49th Annual Macula Society Meeting: New and Emerging Treatments for Retinal Diseases
Jun 2200:11:50Tap to summarizeDrs. Yiu and Emami wrap-up their discussion of the 49th Annual Macula Society Meeting, focusing on new and emerging treatments for retinal diseases—such as gene therapies and longer‑acting eye injections—and reflect on both their promise and current limitations. They note that while these advances, along with tools like AI and multi-omics, are exciting, they are only beginning to influence everyday clinical practice and patient counseling.
Transcribe →Can we actually slow the progression of type 1 diabetes after diagnosis?
Jun 1900:04:40Tap to summarizeThis episode of the PeerDirect Medical News Podcast highlights three major developments shaping diabetes and hematologic oncology care. First, the FDA expanded approval of teplizumab for selected children and adolescents with newly diagnosed Stage 3 type 1 diabetes, making it the first therapy to modify disease progression after diagnosis by preserving beta-cell function. Additional stories review evidence supporting continuous glucose monitoring in basal insulin-treated type 2 diabetes and promising Phase III data showing talquetamab-based bispecific antibody regimens improve outcomes in relapsed or refractory multiple myeloma.
Transcribe →Revisiting Atopic March in the Era of Type 2 Inflammation
Jun 1600:13:52Tap to summarizeDrs. Gupta and Newhall discuss how the traditional idea of the atopic march—eczema progressing to food allergy, asthma, and allergic rhinitis—may be too simplistic and does not always match what they see in the clinic, given what is now known about shared type 2 inflammation, cytokine pathways, and barrier dysfunction across organs. They note that these allergic conditions often arise in parallel rather than in sequence. They suggest using the atopic march as a way to talk about risk, while focusing on early skin protection, timely food allergen introduction, and emerging biologic treatments like dupilumab to potentially reshape a child’s long-term allergic trajectory.
Transcribe →Can one kidney drug expand treatment to millions more patients?
Jun 1100:04:52Tap to summarizeThis episode of the PeerDirect Medical News Podcast reviews three developments with potential implications across nephrology, oncology, and public health. Highlights include the FIND-CKD trial showing finerenone may slow disease progression in chronic kidney disease patients without diabetes, seven-year CROWN trial data demonstrating durable long-term disease control with lorlatinib in advanced ALK-positive lung cancer, and a JAMA Network Open study linking measles-related vitamin A misinformation to increased toxic exposures. Together, these findings underscore evolving treatment paradigms and the growing impact of health communication on patient outcomes.
Transcribe →